|
產(chǎn)品介紹
|
|
品名
|
Monoclonal Antibody to Human Factor H#1
|
|
貨號(hào)
|
A229
|
|
規(guī)格
|
100 μL
|
|
同種型
|
IgG1k
|
|
蛋白質(zhì)濃度
|
> 1.0-1.2 mg/mL
|
|
緩沖液
|
Borate Buffered Saline
|
|
物種交叉反應(yīng)
|
Horse, Cynomolgus Monkey
|
|
儲(chǔ)存
|
≤ 30 days 2°C to 8 °C
> 30 days ≤ –20 °C
|
|
使用說(shuō)明
|
For Research Use Only. Not for use in diagnostic procedures
|
|
背景
|
Factor H is a fluid phase complement regulatory protein consisting of a single peptide chain of 20 short consensus repeat segments or CCP’s with a molecular weight of approximately 155 KD. Factor H regulates the alternative pathway of the complement system by modifying activity of the “feedback loop.” It does this in three ways. First, it is a co-factor for the serine protease Factor I, which cleaves C3b to iC3b. iC3b has no hemolytic or amplification function, but may be bound by complement receptors. Second, Factor H prevents the formation of and accelerates the disassociation of the alternative pathway C3 convertase, C3bBb from cell surfaces. Finally, Factor H binds to polyanions on host cell surfaces and tissue matrices, such as basement membranes, blocking deposition of C3b. This later activity is leveraged by many pathogens as a mode of complement evasion. 1
|
|
描述
|
All of Quidel’s monoclonal antibodies to complement antigens were prepared using intact complement proteins and are purified from mouse ascites fluid via protein A affinity chromatography. The prepared monoclonal antibodies are buffer exchanged in Borate Buffered Saline containing 0.02% NaN3.
|
|
應(yīng)用
|
Applications of this antibody have been evaluated by various research facilities, and include EIA, 7 RIA, Western Blot, 4 IHC, 5 Flow Cytometry, 6 and Ligand Dot Blot. 6
|
|
參考資料
|
1、Kraiczy, P., Wu?rrzner, R. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol Immunol 43:21-44 (2006).
2、Sivaprasad, S. and Chong, N.V. The complement system and age related macular degeneration. Eye (2006), 1-6.
3、Atkinson, J.P., et al. Complement factor H and the hemolytic uremic syndrome. JEM Vol. 204, No. 6, June 11, 20071245–1248.
4、Fedarko, N.S., et al. Factor H binding to bonesialoprotein and osteopontin enables tumor cell evasion of complement mediated attack. JBC 27%:22 (2000).
|
